Delivery Across the Blood-Brain Barrier

The blood-brain barrier (BBB) and the blood cerebrospinal fluid barrier (BCSFB) exist to protect the brain, stringently regulating the passage of substances in and out. This report examines the ways in which these natural barriers may be overcome or circumvented to ensure that drugs can reach their intended target in the brain.

New Emerging R&D and Clinical Trial Locations

This report examines and compares the next wave of clinical trial and drug development locations. Over the next 5 to 10 years, the countries identified in this report will become increasingly important as offshoring and outsourcing destinations.

The CMO Market Outlook to 2017

This report examines the markets for contract manufacturing of finished dose forms and clinical quantity pharmaceuticals. The report forecasts CMO markets for the US, Western Europe, Eastern Europe, China, India, Other Asia, Latin America and the rest of the world to 2017. Drivers and restraints for each regional market as well as the global market are also examined.

Avastin fails to top any individual market in 2011

The high level of commercial success experienced by the key companies in the cancer therapy market makes the market extremely attractive to drug developers. Treatment of cancer has shifted toward a more focused attack on the disease with targeted therapies. However, austerity packages imposed could see slower commercial growth and larger generic erosion of key brands.

Drug Discovery for Rare Diseases

In comparison with major diseases, the targeting of rare diseases poses many different challenges, necessitating consideration of bespoke R&D strategies for drug discovery efforts to be successful. This report examines the role that low disease prevalence plays in determining the most suitable R&D path.

Drug Delivery Partnership Strategies

This report builds on interviews with industry executives, case studies, and analysis of deal and other market data to set out a set of strategies to optimally partner for enhanced drug delivery products.

Innovations in the Delivery of Peptides

Peptides are an important class of drugs, but their potential for treating chronic diseases will be fully realized only if more acceptable delivery methods than daily injections can be developed. Recognition of this has led to advances in oral, intranasal, inhaled, transdermal, and buccal formulations. This report analyses the products and companies at the forefront of such research.

The Computed Tomography (CT) Market Outlook to 2016

This report provides comprehensive coverage of the global CT market, covering low- to high-slice scanners and analyzing the major factors affecting revenue growth. Quantitative estimates of revenue by market segment and geography are provided. The report assesses the demand side of the CT scanner business strategically analyzes the vendor competitive landscape.

Innovations in Molecular Diagnostics for Infectious Diseases

This report examines the opportunities presented to the developers of molecular diagnostics by the emergence of novel/variant pathogens and ways in which new molecular testing technologies are being translated into superior diagnostic products in areas such as healthcare-associated infections; HPV infections, blood-borne viral infections and respiratory viral infections.

Impact of Biomarkers in Alzheimer's Disease - Dx-Rx collaboration paves the way for personalized medicine

Diagnostic and prognostic biomarkers will help to identify patients with early Alzheimer’s disease, while pharmacogenetic biomarkers can inform prescribing decisions and form the basis of personalized medicine. Biomarkers are at the heart of the development of two high-risk pipeline drugs, bapineuzumab and solanezumab, with combined peak-year sales forecasts of $6.6bn in the seven major markets.

Global Generics

Datamonitor's industry profiles are an essential resource for top-level data and analysis. This profile includes data on market size and segmentation, plus textual analysis of the key trends and competitive landscape, demographic information, and descriptions of the leading companies. 

Generics in Japan

Datamonitor's industry profiles are an essential resource for top-level data and analysis. This profile includes data on market size and segmentation, plus textual analysis of the key trends and competitive landscape, demographic information, and descriptions of the leading companies.

Global Health Care Equipment

Datamonitor's industry profiles are an essential resource for top-level data and analysis. This profile includes data on market size and segmentation, plus textual analysis of the key trends and competitive landscape, demographic information, and descriptions of the leading companies.

OTC Pharmaceuticals: Global Industry Guide

OTC Pharmaceuticals: Global Industry Guide is an essential resource for top-level data & analysis covering the OTC Pharmaceuticals industry. It includes data on market size & segmentation, textual analysis of the key trends & competitive landscape, & profiles of the leading companies. This incisive report provides expert analysis on a global, regional & country basis.

Trends in mHealth and Telemedicine

Worldwide societal, technological, and economic changes are affecting the way people live and look after their health. New, more efficient and cost effective ways of delivering healthcare are needed. mHealth and telemedicine offer a solution to this problem. The growth potential of the mHealth and telemedicine market is only now becoming apparent as more healthcare and ICT vendors take part.

Neurologists remain loyal to brands in genericized market

The epilepsy market has become increasingly competitive following the launch of Vimpat (lacosamide; UCB) in the US in May 2009 and patent expiries of the top four second-generation anticonvulsant drugs over 2008–09. However, the switching of stable epilepsy patients to a generic alternative remains controversial due to physicians’ concerns surrounding compromised seizure control.

Aging populations will lead to a growing number of active epilepsy diagnoses

Datamonitor has estimated that there were approximately 4.5 million cases of diagnosed active epilepsy in 2010 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). Almost half of this patient population lives in the US. Datamonitor expects prevalence rates to remain constant over the forecast period (2010–20).

Past successes hard to emulate in highly genericized market

Sales of antiepileptic drugs totaled $3.5 billion in 2009 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK). Datamonitor anticipates the combination of continuing strong historical growth dynamics and the uptake of the late-stage pipeline drugs to result in the market value peaking at $5.1 billion in 2017, after which a new wave of patent expiries hits the US.